The combination of these agents raises concerns about the risk of infection, considering the inhibition of RANK and RANKL expressed in cells of the immune system by denosumab treatment and the inhibition of signalling pathways important and necessary for immune system function by the treatments used in IRD therapy. This evidence concerns the gene TNFRSF11A and infection.